| Overview |
| bs-1185R-PE |
| TRAF3 Polyclonal Antibody, PE Conjugated |
| WB, FCM |
| Human, Mouse |
| Rat |
| Specifications |
| PE |
| Rabbit |
| KLH conjugated synthetic peptide derived from human TRAF3 |
| 101-200/568 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 7187 |
| Q13114 |
| Cytoplasm |
| CAP1; LAP1; CAP-1; CRAF1; IIAE5; CD40bp; TNF receptor-associated factor 3; CD40 receptor-associated factor 1; CD40-binding protein; LMP1-associated protein 1; TRAF3 |
| Regulates pathways leading to the activation of NF-kappa-B and MAP kinases, and plays a central role in the regulation of B-cell survival. Part of signaling pathways leading to the production of cytokines and interferon. Required for normal antibody isotype switching from IgM to IgG. Plays a role T-cell dependent immune responses. Plays a role in the regulation of antiviral responses. Is an essential constituent of several E3 ubiquitin-protein ligase complexes. May have E3 ubiquitin-protein ligase activity and promote 'Lys-63'-linked ubiquitination of target proteins. Inhibits activation of NF-kappa-B in response to LTBR stimulation. Inhibits TRAF2-mediated activation of NF-kappa-B. Down-regulates proteolytic processing of NFKB2, and thereby inhibits non-canonical activation of NF-kappa-B. Promotes ubiquitination and proteasomal degradation of MAP3K14. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
Powered by Bioz